Currently searching for a PhD position

Please note that this is a real resume, and I’m looking for a PhD position at the moment. I made this resume following a recommendation that it would effectively showcase my qualifications to prospective supervisors.

I hold a master’s degree in Biochemistry and Molecular Biology from Fujian Medical University and have 5 years of experience in the field of precision medicine for cancer, specializing in NGS Bioinformatics analysis and statistical work. I am seeking a PhD Position in the field of molecular biology or Bioinformatics related to cancer or other interesting topic. I have participated in multiple research projects and involved in the publication of four papers\(^{1-4}\) to date. Specifically, I played a significant role in three studies \(^{1, 3-5}\) focused on the analysis of tumor cohort NGS data, where my responsibilities primarily involved data compilation, statistical analysis, and visualization.

If you are interested in my background and skills, please feel free to contact me.

Sanming University

B.S. in biotechnology

Sanming, China

2009

Thesis: Analysis of planting resources of Anoectochilus based on ITS sequence

Fujian Medical University

M.S. in Biochemistry and Molecular Biology

Fuzhou, China

2013

Thesis: The interaction between the hepatitis B virus spliced protein HBSP and the hepatic cell UXT and their effects on the NF-κB pathway.

Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences

Ph.D. candidate in Biochemistry and Molecular Biology

Shanghai, China

2016

• Research direction: Mechanism Analysis of Post-transcriptional Modification Process, including RNA splicing and protein ubiquitination modification.
• Performed molecular experiments to explore how QKI-5 protein regulates the ADD3 gene alternative splicing in cancer\(^{2}\).
• Explore the role of SPSB1-mediated ubiquitination in the initiation and progression of tumorigenesis.

Medical data analysis

OrigiMed Co., Ltd

Shanghai, China

2018 - 2023

• Performed data visualization of the article’s results, which profiled the genomic features and its therapeutic potential in small cell lung cancer\(^{4}\).
• Analyse gastric cancer pts’s clinical NGS testing results to explore the potential implication for gastric cancer therapy in Chinese Patients\(^{3}\).
• Investigated solid tumor’s somatic alterations in Chinese to reveal population molecular profiling\(^{1}\).
• Investigated Structure variants of cancer-related genes in pan-cancer systemically\(^{6}\).

Medical data analysis

OrigiMed Co., Ltd

Shanghai, China

2018 - 2023

• Curating findings or conclusions of precise therapy (target/immunology therapy) from literature or guidelines (NCCN, et al.) into an actionable in-house knowledge database.
• Generate Real world data reports, whose content includes gene prevalence, gene variant-related clinical prognosis, and gene-related clinical insights, to help medical or biological professionals.
• Analyzed label-free quantitative proteomics data analysis.
• Cooperating with the AI engineer who performs deep learning algorithms, designing an AI model for predicting gene variant existence in tumor samples to aid in pharmaceutical recruitment\(^{5}\).

Introduction to R Language for Beginners.

Instructor of R and Data Analysis Training Courses in Department of Medical Knowledge Management at OrigiMed Co., Ltd

Shanghai, China

2020

Medical Molecular Biology Experiments Course.

Teaching assistant of Medical Molecular Biology Experiments Course at Fujian Medical University

Fuzhou, China

2014 - 2016

1. Landscape of Somatic Alterations in Large-Scale Solid Tumors from an Asian Population.

Nat Commun 13, no. 1 (Jul 23 2022): 4264. https://dx.doi.org/10.1038/s41467-022-31780-9.

Shanghai, China

2022

Wu, L., H. Yao, H. Chen, A. Wang, K. Guo, W. Gou, Y. Yu, X. Li, M. Yao, S. Yuan, F. Pang, J. Hu, L. Chen, W. Liu, J. Yao, S. Zhang, X. Dong, W. Wang, J. Hu, Q. Ling, S. Ding, Y. Wei, Q. Li, W. Cao, S. Wang, Y. Di, F. Feng, G. Zhao, J. Zhang, L. Huang, J. Xu, W. Yan, Z. Tong, D. Jiang, T. Ji, Q. Li, L. Xu, H. He, L. Shang, J. Liu, K. Wang, D. Wu, J. Shen, Y. Liu, T. Zhang, C. Liang, Y. Wang, Y. Shang, J. Guo, G. Liang, S. Xu, J. Liu, K. Wang, and M. Wang.

2. Qki-5 Regulates the Alternative Splicing of Cytoskeletal Gene Add3 in Lung Cancer.

J Mol Cell Biol 13, no. 5 (Aug 18 2021): 347-60. https://dx.doi.org/10.1093/jmcb/mjaa063.

Shanghai, China

2021

Wang, J. Z., X. Fu, Z. Fang, H. Liu, F. Y. Zong, H. Zhu, Y. F. Yu, X. Y. Zhang, S. F. Wang, Y. Huang, and J. Hui.

3. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.

Oncologist 26, no. 5 (May 2021): e756-e68. https://dx.doi.org/10.1002/onco.13695.

Shanghai, China

2021

Yu, P., Y. Wang, Y. Yu, A. Wang, L. Huang, Y. Zhang, W. Liu, H. Wu, M. Yao, Y. A. Du, and X. Cheng.

4. Comprehensive Genomic Profiling of Small Cell Lung Cancer in Chinese Patients and the Implications for Therapeutic Potential.

Cancer Med 8, no. 9 (Aug 2019): 4338-47. https://dx.doi.org/10.1002/cam4.2199.

Shanghai, China

2019

Hu, J., Y. Wang, Y. Zhang, Y. Yu, H. Chen, K. Liu, M. Yao, K. Wang, W. Gu, and T. Shou.

5. Use of an Artificial Intelligence (Ai) -Based Pre-Screening Tool for Patients with Bladder Cancer with Fibroblast Growth Factor Receptor (Fgfr) Alteration.

Meeting Abstract, Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e13580-e13580. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e13580

Shanghai, China

2023

Shi, G. B., Y. F. Yu, A. D. Wang, Y. Liu, and X. L. Shi.

6. Systematic analysis of actionable gene fusions by NGS-based in pancancer for precision oncology in China.

Meeting Abstract, Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) e15072-e15072. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e15072

Shanghai, China

2022

S Yuan, R Li, K Wang, X Shi, Y Yu, F Liu, A Wang, L Mei, H Chen